Growth suppression is usually most evident during the first year of inhaled steroid therapy. Steroid-induced changes in bone metabolism may contribute to this growth suppression. The aim of the present study was to evaluate the changes in biochemical markers of bone metabolism in relation to adrenal and growth suppression during the initiation phase of inhaled steroid therapy. Seventy-five school-aged children with new asthma were enrolled into budesonide (BUD, n ϭ 30), fluticasone propionate (FP, n ϭ 30) or cromone (CROM, n ϭ 15) treatment groups. BUD dose was 800 g/d during the first two months and 400 g/d thereafter. The respective FP doses were 500 and 200 g/d. Biochemical markers of bone metabolism were measured before treatment and after 2 and 4 mo of therapy. In the control (CROM) group, the mean concentrations of serum osteocalcin (OC), carboxyterminal propeptide of type I procollagen (PICP) (formation markers) and type I collagen carboxyterminal telopeptide (ICTP) (degradation marker) tended to increase. In the BUD group, OC and PICP decreased during the 4 mo by a mean of 23% (p Ͻ 0.001) and 15% (p Ͻ 0.05), respectively, while ICTP did not change significantly. In the FP group, OC and ICTP decreased during the first 2 mo by a mean of 19% (p Ͻ 0.01) and 21% (p Ͻ 0.01), respectively, returning to the pretreatment level at 4 mo, while PICP tended to increase during the 4 mo (14%, p ϭ 0.12).
In the steroid treated children whose height SD score decreased during the first 12 mo of therapy, both OC and PICP decreased during the first 4 mo by a mean of 20% (p Ͻ 0.01) and 21% (p Ͻ 0.001), respectively. In those children who had no growth suppression, the changes were not significant: Ϫ4% in OC and ϩ13% in PICP. Furthermore, in children who developed evidence of adrenocortical suppression (on the basis of a low-dose ACTH test), OC decreased more (23%, p Ͻ 0.01) than in those with normal adrenocortical function (10%, p ϭ 0.06). In conclusion, both inhaled BUD and FP caused dose-dependent effects on biochemical markers of bone metabolism. The children who developed growth or adrenocortical suppression were likely to have changes also in bone metabolism. Asthmatic children treated with inhaled steroids seem to attain normal adult height (1) . Despite this, inhaled steroids may at least temporarily suppress adrenocortical function (2, 3) , growth (4, 5) , and bone metabolism (6, 7) . Glucocorticoids affect calcium metabolism (8, 9) , and they can reduce bone formation by impairing the function of osteoblasts (10) . Therefore, long-term use of inhaled steroids can cause osteopenia, at least in adults (11, 12) . There is a difference in the doseresponse relation between efficacy and systemic adverse effects of inhaled steroids. A plateau in the efficacy is reached at relatively low doses (13) , while a linear relation between the dose and the effects on the adrenocortical function and bone metabolism continues for much higher doses (14) .
OC, the most abundant noncollagenous protein in bone matrix, is produced mainly by osteoblasts. Therefore, it has been used as a marker of osteoblastic activity (15, 16) . Bone formation can be evaluated also by measuring serum concentrations of PICP, which is cleaved from type I procollagen during collagen synthesis (17) . Collagen breakdown products, such as serum ICTP, have been used as an indicator of bone matrix degradation (18 -20) .
occasions. All serum specimens were stored at Ϫ70°C until analyzed. The samples of each patient were analyzed in the same assay. The intra-assay coefficients of variation (CV) were calculated from the actual series. PICP was determined by RIA (Orion Diagnostica, Espoo, Finland); the sensitivity of the method was 1.2 g/L, and the intra-assay CV was 11.0% for low and 10.6% for high values. The RIA for OC (OSCAtest, Brahms Diagnostica, Berlin, Germany) had the sensitivity of 1.8 g/L, and the intra-assay CV was 9.3% for low and 10.1% for high values. The sensitivity of the ICTP RIA (Orion Diagnostica) was 0.5 g/L, and its intra-assay CV was 14 Statistical analyses. The data were analyzed by SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). Means, SD, and 95% confidence intervals (95% CI) were determined for continuous variables. For individual patients, the percentage changes of the bone markers were calculated from the baseline (before treatment) values. The statistical significance of the differences in continuous variables was calculated using the t test or the analysis of variance, and the age, sex, and baseline values of bone markers were taken into account as confounding factors. The noncontinuous data were analyzed by the 2 -test.
RESULTS
The age, sex, height, weight, FEV 1 , and biochemical markers of bone metabolism in the three treatment groups at the beginning of the study are presented in Table 1 . At the beginning, serum PICP was slightly higher in the BUD than in the FP or CROM groups (p Ͻ 0.05), while the other parameters did not differ. During the treatment, the symptoms of asthma resolved, and FEV 1 improved significantly in both steroid groups. At 4 mo, FEV 1 was above the baseline in the BUD by a mean of 8.4% (95% CI, 3.2-13.6; p Ͻ 0.01), and 5.4% (95% CI, 1.6 -9.1; p Ͻ 0.01) above the baseline in the FP group (there were no differences between the steroid groups). In the CROM group, FEV 1 was below the baseline level by a mean of 1.5% (95% CI, Ϫ6.1 to 3.1; NS) (p Ͻ 0.05 versus both steroid groups).
Biochemical markers of bone metabolism. The percentage changes of the markers of bone metabolism in the three treatment groups are presented in Figure 1 . The age of the children and the baseline concentrations of the bone markers were taken into account as confounding factors in the statistical analyses. Of the markers of bone formation, OC decreased in the BUD and FP groups, while PICP decreased only in the BUD group. The bone degradation marker ICTP decreased in the FP group during the first 2 mo, returning close to the 259 BONE METABOLISM AND INHALED STEROIDS starting level by 4 mo; the changes in the BUD group were not significant. In the CROM group, all bone markers tended to increase slightly during the 4-mo follow-up period, but the changes were not significant. The changes of the bone markers were not different in boys compared with girls. The results were the same when girls older than 10 y and boys older than 12 y were excluded from the analyses (to eliminate the possible influence of the physiologic late pubertal decrease in PICP and ICTP concentrations (24) . Likewise, the severity of asthma did not have any effect on the baseline values or on the changes of bone marker concentrations.
Bone metabolism in relation to adrenocortical function and growth. At 4 mo, the low-dose ACTH-test result was normal in all CROM-treated children and abnormal in 14 (23%) of the steroid-treated children. In the steroid-treated children with suppressed adrenocortical function, OC decreased by a mean of 23% (95% CI, 9% to 36%, p Ͻ 0.01) and PICP decreased 9% (95% CI, Ϫ27% to 9%, NS), while in the children with a normal ACTH-test result the respective changes were Ϫ10% (95% CI, Ϫ20% to 0%, NS) and ϩ4% (95% CI, Ϫ8% to 16%, NS) (Fig. 2) . In the children with an abnormal ACTH-test result, ICTP decreased by 2% (mean, NS), while in the children with a normal ACTH-test result it decreased 9% (NS).
The height SD score decreased during the 4-mo treatment period in 26 (43%) and did not decrease in 34 (57%) steroid treated children. OC decreased significantly in the children with decreasing height SD score (16%; p Ͻ 0.01), while the changes in PICP were not significant ( Table 2) . Twenty-three Values are the mean Ϯ SD. * The patients in the BUD and FT groups were heavier than those in the CROM group (p Ͻ 0.05). † PICP was higher in the BUD than in the FT or CROM groups (p Ͻ 0.05). Otherwise, the groups did not differ significantly.
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of the original steroid-treated children used the same medication throughout the 12-mo follow-up period. The height SD score decreased in 13 (57%) and did not decrease in 10 (43%) of these children. The bone formation markers OC and PICP decreased significantly in the children with decreasing height SD score but not in those whose height SD score did not decrease ( Table 2 ). The changes in weight for height were small during the 4-mo observation period; mean change ϩ 0.73% in the BUD, ϩ1.7% in the FP and Ϫ0.6% in the CROM group (all nonsignificant). The weight for height increased during the 4-mo treatment period in 29 (48%) and did not increase in 31 (52%) of the steroid treated children. The changes in OC, PICP, and ICTP did not differ in these two patient groups.
DISCUSSION
In this prospective study in children with newly diagnosed asthma, both BUD and FP had measurable effects on biochemical markers of bone metabolism. The two bone formation markers, PICP and OC, decreased significantly during BUD treatment. The effects of FP, when used at half doses compared with BUD, were less prominent, and in the case of PICP, partly opposite. The changes in the bone degradation marker ICTP concentrations were less constant. All of these changes were steroid-dose dependent, but not explained by the age of the children, and they were associated with suppression of growth and adrenocortical function.
Of the markers of bone formation, OC seemed to be more sensitive than PICP to the effects of inhaled steroids. As OC is closely associated with bone mineralization (25) , our data suggest that this later phase of bone formation is more prone to become depressed during corticosteroid treatment than the earlier phase of collagen synthesis. In the BUD-treated children, OC decreased at both high and low doses, while FP caused a significant decrease only at high doses. Accordingly, PICP decreased continuously at both BUD doses, whereas FP caused no decrease at all. Our findings are opposite to the results of Birkebaek et al. (26) and Hedlin et al. (27) , who found no decrease in OC during inhaled steroid therapy. In these studies, the treatment period lasted less than 4 wk, which is perhaps too short to cause significant changes. Our findings are consistent with those of Sorva et al. (6) , who treated their patients for 6 mo with BUD, and found a significant decrease in OC. Our data suggest that BUD diminishes bone formation, both mineralization and collagen synthesis, at least transiently, even at a dose of 400 g/d, whereas FP seems to diminish only the later mineralization phase of bone formation, and only at 500 g/d doses. These results are consistent with the recent study of Reilly et al. (28) , who found that FP is less likely than BUD to affect trabecular bone mineral density. On the other hand, during CROM treatment, both markers of bone formation tended to increase, probably reflecting normal agedependent growth and increase in bone mass (29, 30) .
The bone matrix degradation product ICTP decreased in the FP group and did not change in the BUD group. However, not all experts consider serum ICTP a good marker of bone matrix degradation (31) . Our ICTP results are opposite those of Hoekx et al. (32) , who found a minor decrease in BUD users and a slight increase in FP users when the dose for both drugs was 400 g/d. However, in their study, all children had been treated with inhaled corticosteroids before entry, which may have influenced the baseline situation.
In both steroid groups, the changes of the bone resorption marker ICTP concentrations were in general parallel to those of the bone formation markers. This suggests that during inhaled steroid treatment, the coupling of bone formation and degradation is maintained, and the children on inhaled steroids may not be at a particular risk for osteopenia. In the present study, we did not measure bone mineral densities, as the expected changes during this short observation period would probably be minimal. This assumption is supported by a cross-sectional study of König et al. (33) , who found no reduction in bone mineral density in beclomethasone-treated children, even though their OC levels decreased. Likewise, Martinati et al. (34) found no differences in bone mineral densities between bechlomethasone-and CROM-treated children. In two longitudinal studies in children lasting up to 18 mo, neither bechlomethasone nor FP had any significant effects on bone mineral density (35, 36) . On the other hand, high cumulative doses of inhaled steroids have been associated with decreased bone mineral density in adults (12) , and high inhaled steroid doses and short courses of oral corticosteroids have been found to reduce the acquisition of bone mineral in children (37). Values are mean percentage changes with 95% confidence intervals in parentheses. * Only the children who were treated with the same drug throughout the 12 mo are included. † The changes in PICP differed significantly from those whose height SD score did not decrease during the 12-mo follow-up (p Ͻ 0.01).
BONE METABOLISM AND INHALED STEROIDS
The serum concentrations of the bone formation marker OC decreased especially in those children who developed biochemical evidence of adrenocortical suppression. Thus, children who are prone to develop adrenocortical suppression during inhaled steroid treatment seem also to be at increased risk for adverse effects on bone metabolism. Likewise, children with decreasing bone formation (OC or PICP decreased) at the initiation phase of inhaled steroid therapy are likely to be at risk for growth suppression. Of course, the complex phenomenon of growth is only partly mediated through bone metabolism, but it is known that normal growth and an increase of bone mass influence the markers of bone metabolism (29, 30, 38) . The bone marker concentrations are quite stable or increase slightly until the age of 12 to 14 y, where after they decrease to the adult level (24) . The physiologic decrease in bone marker concentrations reported during late puberty does not seem to explain the changes seen in our steroid treated children because the exclusion of the oldest children did not change our finding. Growth suppression is usually most evident during the first year of inhaled steroid therapy (5, 39) . Our previous (3) and present findings suggest that the changes in adrenocortical function and bone metabolism during the initiation phase of inhaled steroid therapy may predict growth suppression.
In conclusion, during the first 4 mo of inhaled steroid therapy, both BUD and FP had dose-dependent effects on biochemical markers of bone metabolism. OC was more apt than PICP to decrease during inhaled steroid treatment, suggesting that the mineralization phase of bone formation may be more sensitive to corticosteroid excess than the phase of collagen synthesis. The children who developed growth or adrenocortical suppression were likely also to have changes in bone metabolism during the initiation phase of inhaled steroid therapy.
